Výsledky vyhledávání - "Denni M. Zborowski"

Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

Autor: Gary M. Clark, Denni M. Zborowski, Lesley Seymour, Michelle Savoie, Jennifer L. Culbertson, Marlo Whitehead, Frances A. Shepherd

Publikováno v: Journal of Thoracic Oncology. 1:837-846

Introduction Erlotinib (Tarceva®) has demonstrated a survival benefit in unselected patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because not all patients benefit from erlotinib, epidermal growth factor rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1ae944ad1174aa93f562e4cd6dd113
https://doi.org/10.1097/01243894-200610000-00013

Zobrazit plný text záznamu

Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib

Autor: Gary M, Clark, Denni M, Zborowski, Jennifer L, Culbertson, Marlo, Whitehead, Michelle, Savoie, Lesley, Seymour, Frances A, Shepherd

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(8)

Erlotinib (Tarceva) has demonstrated a survival benefit in unselected patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because not all patients benefit from erlotinib, epidermal growth factor receptor (EGFR) pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7555540c72dd22a04712e2477a46135d
https://pubmed.ncbi.nlm.nih.gov/17409968

Zobrazit plný text záznamu

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

Autor: Frances A. Shepherd, Keyue Ding, Marlo Whitehead, Gary M. Clark, Lesley Seymour, Denni M. Zborowski, Pedro Santabárbara

Publikováno v: Clinical lung cancer. 7(6)

Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo was demonstrated in the National Cancer Institute of Canada Clinical T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b4510dd177c0f89ff0e86578655d769
https://pubmed.ncbi.nlm.nih.gov/16800960

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání